Design and Synthesis of New Cholesterol-Conjugated 5-Fluorouracil: A Novel Potential Delivery System for Cancer Treatment

Cholesterol-conjugated 5-fluorouracil prodrugs were designed to be carried in vivo via low density lipoproteins (LDL) and subsequently undergo LDL-receptor-mediated internalisation into cancer cells. In vivo anti-cancer evaluation was performed using 5-fluorouracil-cholesterol conjugate in a mouse m...

Descripción completa

Detalles Bibliográficos
Autores principales: Radwan, Awwad A., Alanazi, Fares K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6271816/
https://www.ncbi.nlm.nih.gov/pubmed/25162958
http://dx.doi.org/10.3390/molecules190913177
_version_ 1783377014661578752
author Radwan, Awwad A.
Alanazi, Fares K.
author_facet Radwan, Awwad A.
Alanazi, Fares K.
author_sort Radwan, Awwad A.
collection PubMed
description Cholesterol-conjugated 5-fluorouracil prodrugs were designed to be carried in vivo via low density lipoproteins (LDL) and subsequently undergo LDL-receptor-mediated internalisation into cancer cells. In vivo anti-cancer evaluation was performed using 5-fluorouracil-cholesterol conjugate in a mouse model. The obtained prodrugs were more potent than 5-fluorouracil control drug at the same 5-fluorouracil content (3 mg·kg(−1)).
format Online
Article
Text
id pubmed-6271816
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-62718162018-12-27 Design and Synthesis of New Cholesterol-Conjugated 5-Fluorouracil: A Novel Potential Delivery System for Cancer Treatment Radwan, Awwad A. Alanazi, Fares K. Molecules Article Cholesterol-conjugated 5-fluorouracil prodrugs were designed to be carried in vivo via low density lipoproteins (LDL) and subsequently undergo LDL-receptor-mediated internalisation into cancer cells. In vivo anti-cancer evaluation was performed using 5-fluorouracil-cholesterol conjugate in a mouse model. The obtained prodrugs were more potent than 5-fluorouracil control drug at the same 5-fluorouracil content (3 mg·kg(−1)). MDPI 2014-08-26 /pmc/articles/PMC6271816/ /pubmed/25162958 http://dx.doi.org/10.3390/molecules190913177 Text en © 2014 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Article
Radwan, Awwad A.
Alanazi, Fares K.
Design and Synthesis of New Cholesterol-Conjugated 5-Fluorouracil: A Novel Potential Delivery System for Cancer Treatment
title Design and Synthesis of New Cholesterol-Conjugated 5-Fluorouracil: A Novel Potential Delivery System for Cancer Treatment
title_full Design and Synthesis of New Cholesterol-Conjugated 5-Fluorouracil: A Novel Potential Delivery System for Cancer Treatment
title_fullStr Design and Synthesis of New Cholesterol-Conjugated 5-Fluorouracil: A Novel Potential Delivery System for Cancer Treatment
title_full_unstemmed Design and Synthesis of New Cholesterol-Conjugated 5-Fluorouracil: A Novel Potential Delivery System for Cancer Treatment
title_short Design and Synthesis of New Cholesterol-Conjugated 5-Fluorouracil: A Novel Potential Delivery System for Cancer Treatment
title_sort design and synthesis of new cholesterol-conjugated 5-fluorouracil: a novel potential delivery system for cancer treatment
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6271816/
https://www.ncbi.nlm.nih.gov/pubmed/25162958
http://dx.doi.org/10.3390/molecules190913177
work_keys_str_mv AT radwanawwada designandsynthesisofnewcholesterolconjugated5fluorouracilanovelpotentialdeliverysystemforcancertreatment
AT alanazifaresk designandsynthesisofnewcholesterolconjugated5fluorouracilanovelpotentialdeliverysystemforcancertreatment

Ejemplares similares